Pheochromocytoma and paraganglioma (PPGL)

What changed: Pheochromocytoma and paraganglioma (PPGL)

Indication page →

Every dated change on the records linked to Pheochromocytoma and paraganglioma (PPGL), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval1Guideline2Milestone7This record1

FollowWatch this record and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-10This recordPheochromocytoma and paraganglioma (PPGL)
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 1

2025MilestonePheochromocytoma and paraganglioma (PPGL)
Belzutifan approved for PPGL
FDA, 14 May 2025, LITESPARK-015 cohort A1; first oral therapy for the disease.

2024 · 1

2024MilestoneSunitinib
FIRSTMAPPP: sunitinib delays progression
Baudin and colleagues, Lancet: first randomised trial in metastatic PPGL.

2018 · 1

2018Milestone131I-MIBG (iobenguane I-131) therapy
High-specific-activity 131I-MIBG (Azedra) approved
FDA, July 2018, for unresectable MIBG-positive PPGL; later discontinued commercially.

2014 · 3

2008 · 1

2008ApprovalIobenguane I-123
Iobenguane I-123 approved in US
Detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests

2000 · 1

2000MilestonePheochromocytoma and paraganglioma (PPGL)
SDHD mutations in hereditary paraganglioma
Baysal and colleagues, Science: metabolic enzyme genes as tumour suppressors.

1926 · 1

1926MilestonePheochromocytoma and paraganglioma (PPGL)
First successful resection (Roux in Lausanne, Mayo in Rochester)
A milestone in how this cancer is treated.

1886 · 1

1886MilestonePheochromocytoma and paraganglioma (PPGL)
Fränkel describes bilateral adrenal tumours in an 18-year-old
Later shown by genetic analysis to be a case of MEN2.